Agomab Therapeutics (AGMB)

Executive Summary

Agomab Therapeutics (Nasdaq: AGMB) is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for immune and inflammatory diseases, with an initial emphasis on chronic fibrotic conditions with high unmet need. Headquartered in Antwerp, Belgium, the company recently completed its IPO in February 2026, raising capital to advance its pipeline. The lead program, AGMB-129, is a small molecule inhibitor targeting a novel fibrosis pathway and is currently in a Phase 2 trial for fibrostenotic Crohn’s disease (NCT05843578), with expected completion in September 2026. Additionally, AGMB-447, an inhaled biologic for idiopathic pulmonary fibrosis (IPF), is in a Phase 1 study (NCT06181370) with completion anticipated in June 2026. Agomab leverages deep expertise in fibrosis biology to address significant gaps in treatment, aiming to slow or reverse disease progression in patients with limited options. The company’s focus on innovative mechanisms and its recent public listing position it for potential value creation as clinical data mature.

Upcoming Catalysts (preview)

• Q2 2026AGMB-447 Phase 1 Topline Data in IPF75% success
• Q3 2026AGMB-129 Phase 2 Interim or Final Data in Fibrostenotic Crohn's Disease60% success
• Q4 2026Initial Guidance on Regulatory Path for AGMB-12950% success